Investor Relations

Anesiva, Inc. (Nasdaq: ANSV) is a biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for pain management.

The investor pages that follow are your resource for financial information about Anesiva. In this section you will find information about our current and historical share price, analyst coverage, SEC filings, an electronic version of our annual report and frequently asked questions as well as forms to request additional information.

Recent Releases

Dec 31, 2009
Anesiva Announces Merger With Arcion Therapeutics Will Not be Completed

Dec 9, 2009
Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lee's Pharmaceuticals

FORWARD LOOKING STATEMENTS

This website contains forward-looking statements based on certain assumptions and expectations. For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Anesiva's results to differ materially from those indicated by these forward-looking statements, including, without limitation, risks related to the progress, timing and results of Anesiva's clinical trials, intellectual property matters, difficulties or delays in obtaining regulatory approval, and other risks detailed in Anesiva's filings with the Securities and Exchange Commission.